Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shehzad Choudry

Pain Medicine Orlando, FL Medical Doctor

NPI 1194836676 CMS profile 326127

89 W Copeland Dr, Orlando, FL 32806

Open in the dashboard

General payments

$43,593

214 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$45,413 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Shehzad Choudry of Orlando, FL is reported in the CMS Open Payments database as having received $43,593 across 214 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $45,413 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,254 36
2024 General $8,177 35
2023 General $15,531 43
2022 General $4,716 40
2021 General $535 11
2020 General $328 12
2019 General $6,053 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shehzad Choudry
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Shehzad Choudry were reported at $8,254. Among 95 Pain Medicine profiles paid that year, the median was $405 and the middle half received between $116 and $1,740.

Show as a table
Year Shehzad Choudry Pain Medicine median Middle half National median
2019 $6,053 $298 $103–$1,153 $163
2020 $328 $188 $57–$916 $114
2021 $535 $365 $109–$1,150 $132
2022 $4,716 $498 $104–$1,575 $149
2023 $15,531 $334 $108–$1,267 $160
2024 $8,177 $544 $144–$1,302 $164
2025 $8,254 $405 $116–$1,740 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $30,257 89 payments
  2. Avanos Medical $5,133 6 payments
  3. MML US, Inc. $3,097 12 payments
  4. Relievant Medsystems, Inc. $1,026 9 payments
  5. Nevro Corp. $916 19 payments
  6. Boston Scientific Corporation $814 10 payments
  7. Vertos Medical, Inc. $800 8 payments
  8. Stryker Corporation $295 2 payments
  9. Abbott Laboratories $189 4 payments
  10. Teva Pharmaceuticals USA, Inc. $148 8 payments
  11. Other $917 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24,473 10 payments
  2. Travel and Lodging $7,799 28 payments
  3. Food and Beverage $7,090 174 payments
  4. Honoraria $4,200 1 payment
  5. Education $32 1 payment
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $15,991 54 payments
  2. KYPHON EXPRESS II KYPHOPAK TRAY $13,637 16 payments
  3. COOLIEF $4,431 2 payments
  4. ReActiv8 $3,097 12 payments
  5. Intracept Pain $1,026 9 payments
  6. Intracept Pain $1,003 8 payments
  7. Intracept Pain $1,003 8 payments
  8. Intracept Pain $1,003 8 payments
  9. COOLIEF* COOLED RADIOFREQUENCY $617 3 payments
  10. mild Device Kit $546 5 payments
  11. Other $4,388 130 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

509

Median for Pain Management: 951

Drug cost

$6,509

Median for Pain Management: $26,034

Branded share of claims

22.6%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 11 $994
Pregabalin Generic 49 $968
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 47 $779
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 34 $755
Gabapentin Generic 56 $752
Tramadol Hcl Generic 72 $476
Tizanidine Hcl Generic 25 $323
Diclofenac Sodium Generic 26 $273
Tramadol Hcl-Acetaminophen Tramadol Hcl/Acetaminophen Brand 21 $268
Methocarbamol Generic 29 $236

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$128,658

Of which drugs: $2,751

Medicare patients

318

Average age 73

Services billed

3,547

189 women, 129 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 43%
Diabetes 35%
Chronic kidney disease 35%
Depression 34%
Atrial fibrillation 23%
Osteoporosis 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 40 mg J1030 Office 31 34 $163
Injection, methylprednisolone acetate, 1 mg J1010 Office 24 1,240 $129
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 59 169 $49
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 34 310 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PROLATE
  • Forte Bio-Pharma LLC $16
$16 — —
NALOCET
  • Forte Bio-Pharma LLC $4
$4 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

214 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record